Moclobemide Sandoz (Moclobemide)

Moclobemide works by reversibly inhibiting the enzyme monoamine oxidase A (MAO‑A). This enzyme normally breaks down serotonin, norepinephrine and dopamine. By blocking MAO‑A, moclobemide raises the concentrations of these neurotransmitters, which can alleviate depressive symptoms.

The appropriate dose of Moclobemide Sandoz is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for moclobemide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should discuss individual risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moclobemide differs from many antidepressants because it is a reversible MAO‑A inhibitor, offering a lower risk of dietary tyramine interactions compared with irreversible MAO inhibitors. It may be chosen when patients need an alternative to selective serotonin reuptake inhibitors or tricyclic antidepressants, especially if those agents are ineffective or poorly tolerated.

Moclobemide Sandoz should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Moclobemide Sandoz is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

The most serious risks include hypertensive crisis triggered by high‑tyramine foods, serotonin syndrome when combined with other serotonergic drugs, severe liver injury, agranulocytosis, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be educated to seek immediate medical attention if these symptoms occur.

Moclobemide is contraindicated in patients with known hypersensitivity to moclobemide or any formulation components, those currently taking other MAO inhibitors, and individuals with severe liver impairment. Caution is also advised for patients with uncontrolled hypertension, pheochromocytoma, or a history of serotonin syndrome.